CN110607370B - 一种用于人体肿瘤分子分型的基因组合及其应用 - Google Patents
一种用于人体肿瘤分子分型的基因组合及其应用 Download PDFInfo
- Publication number
- CN110607370B CN110607370B CN201910956560.7A CN201910956560A CN110607370B CN 110607370 B CN110607370 B CN 110607370B CN 201910956560 A CN201910956560 A CN 201910956560A CN 110607370 B CN110607370 B CN 110607370B
- Authority
- CN
- China
- Prior art keywords
- gene
- ensg
- engg
- cancer
- sample
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Active
Links
- 108090000623 proteins and genes Proteins 0.000 title claims abstract description 793
- 206010028980 Neoplasm Diseases 0.000 title claims abstract description 115
- 241000282414 Homo sapiens Species 0.000 title claims abstract description 20
- 230000014509 gene expression Effects 0.000 claims abstract description 65
- 201000011510 cancer Diseases 0.000 claims abstract description 47
- 206010006187 Breast cancer Diseases 0.000 claims description 7
- 208000026310 Breast neoplasm Diseases 0.000 claims description 7
- 206010025323 Lymphomas Diseases 0.000 claims description 6
- 206010004593 Bile duct cancer Diseases 0.000 claims description 5
- 206010005003 Bladder cancer Diseases 0.000 claims description 5
- 206010008342 Cervix carcinoma Diseases 0.000 claims description 5
- 206010009944 Colon cancer Diseases 0.000 claims description 5
- 208000001333 Colorectal Neoplasms Diseases 0.000 claims description 5
- 208000008839 Kidney Neoplasms Diseases 0.000 claims description 5
- 206010058467 Lung neoplasm malignant Diseases 0.000 claims description 5
- 206010033128 Ovarian cancer Diseases 0.000 claims description 5
- 206010061535 Ovarian neoplasm Diseases 0.000 claims description 5
- 206010061902 Pancreatic neoplasm Diseases 0.000 claims description 5
- 206010060862 Prostate cancer Diseases 0.000 claims description 5
- 208000000236 Prostatic Neoplasms Diseases 0.000 claims description 5
- 206010038389 Renal cancer Diseases 0.000 claims description 5
- 208000000453 Skin Neoplasms Diseases 0.000 claims description 5
- 208000032383 Soft tissue cancer Diseases 0.000 claims description 5
- 208000024313 Testicular Neoplasms Diseases 0.000 claims description 5
- 206010057644 Testis cancer Diseases 0.000 claims description 5
- 208000000728 Thymus Neoplasms Diseases 0.000 claims description 5
- 208000024770 Thyroid neoplasm Diseases 0.000 claims description 5
- 208000007097 Urinary Bladder Neoplasms Diseases 0.000 claims description 5
- 208000006105 Uterine Cervical Neoplasms Diseases 0.000 claims description 5
- 208000002495 Uterine Neoplasms Diseases 0.000 claims description 5
- 201000005188 adrenal gland cancer Diseases 0.000 claims description 5
- 208000024447 adrenal gland neoplasm Diseases 0.000 claims description 5
- 208000026900 bile duct neoplasm Diseases 0.000 claims description 5
- 201000010881 cervical cancer Diseases 0.000 claims description 5
- 208000006990 cholangiocarcinoma Diseases 0.000 claims description 5
- 201000010982 kidney cancer Diseases 0.000 claims description 5
- 201000007270 liver cancer Diseases 0.000 claims description 5
- 208000014018 liver neoplasm Diseases 0.000 claims description 5
- 201000005202 lung cancer Diseases 0.000 claims description 5
- 208000020816 lung neoplasm Diseases 0.000 claims description 5
- 208000015486 malignant pancreatic neoplasm Diseases 0.000 claims description 5
- 201000002528 pancreatic cancer Diseases 0.000 claims description 5
- 208000008443 pancreatic carcinoma Diseases 0.000 claims description 5
- 201000003437 pleural cancer Diseases 0.000 claims description 5
- 201000000849 skin cancer Diseases 0.000 claims description 5
- 201000003120 testicular cancer Diseases 0.000 claims description 5
- 208000013076 thyroid tumor Diseases 0.000 claims description 5
- 201000005112 urinary bladder cancer Diseases 0.000 claims description 5
- 206010046766 uterine cancer Diseases 0.000 claims description 5
- 201000006972 gastroesophageal adenocarcinoma Diseases 0.000 claims description 4
- 206010041823 squamous cell carcinoma Diseases 0.000 claims description 3
- 210000000653 nervous system Anatomy 0.000 claims description 2
- 210000001541 thymus gland Anatomy 0.000 claims description 2
- 101150044182 8 gene Proteins 0.000 claims 1
- 238000000034 method Methods 0.000 abstract description 24
- 238000005516 engineering process Methods 0.000 abstract description 10
- 230000003902 lesion Effects 0.000 abstract description 7
- 238000013145 classification model Methods 0.000 abstract description 4
- 210000001519 tissue Anatomy 0.000 description 45
- 239000000523 sample Substances 0.000 description 32
- 108091032973 (ribonucleotides)n+m Proteins 0.000 description 16
- 239000012188 paraffin wax Substances 0.000 description 12
- 238000003908 quality control method Methods 0.000 description 10
- 238000012163 sequencing technique Methods 0.000 description 10
- 238000009396 hybridization Methods 0.000 description 9
- 238000002372 labelling Methods 0.000 description 8
- 238000004458 analytical method Methods 0.000 description 6
- 238000002591 computed tomography Methods 0.000 description 6
- 238000003384 imaging method Methods 0.000 description 6
- 210000004072 lung Anatomy 0.000 description 6
- 230000008569 process Effects 0.000 description 6
- 239000002299 complementary DNA Substances 0.000 description 5
- 210000004185 liver Anatomy 0.000 description 5
- 238000002360 preparation method Methods 0.000 description 5
- 238000012216 screening Methods 0.000 description 5
- YBJHBAHKTGYVGT-ZKWXMUAHSA-N (+)-Biotin Chemical compound N1C(=O)N[C@@H]2[C@H](CCCCC(=O)O)SC[C@@H]21 YBJHBAHKTGYVGT-ZKWXMUAHSA-N 0.000 description 4
- 206010027476 Metastases Diseases 0.000 description 4
- 108091034117 Oligonucleotide Proteins 0.000 description 4
- 238000003745 diagnosis Methods 0.000 description 4
- 230000009401 metastasis Effects 0.000 description 4
- 208000037819 metastatic cancer Diseases 0.000 description 4
- 208000011575 metastatic malignant neoplasm Diseases 0.000 description 4
- 238000005406 washing Methods 0.000 description 4
- 239000002699 waste material Substances 0.000 description 4
- 238000004590 computer program Methods 0.000 description 3
- 238000000605 extraction Methods 0.000 description 3
- 239000012634 fragment Substances 0.000 description 3
- 208000014829 head and neck neoplasm Diseases 0.000 description 3
- 230000002055 immunohistochemical effect Effects 0.000 description 3
- 108020004999 messenger RNA Proteins 0.000 description 3
- 206010061289 metastatic neoplasm Diseases 0.000 description 3
- 201000011682 nervous system cancer Diseases 0.000 description 3
- 238000002600 positron emission tomography Methods 0.000 description 3
- 238000012545 processing Methods 0.000 description 3
- 238000011002 quantification Methods 0.000 description 3
- 238000002271 resection Methods 0.000 description 3
- 230000002194 synthesizing effect Effects 0.000 description 3
- 102000007260 Deoxyribonuclease I Human genes 0.000 description 2
- 108010008532 Deoxyribonuclease I Proteins 0.000 description 2
- 102000004190 Enzymes Human genes 0.000 description 2
- 108090000790 Enzymes Proteins 0.000 description 2
- LFQSCWFLJHTTHZ-UHFFFAOYSA-N Ethanol Chemical compound CCO LFQSCWFLJHTTHZ-UHFFFAOYSA-N 0.000 description 2
- JLCPHMBAVCMARE-UHFFFAOYSA-N [3-[[3-[[3-[[3-[[3-[[3-[[3-[[3-[[3-[[3-[[3-[[5-(2-amino-6-oxo-1H-purin-9-yl)-3-[[3-[[3-[[3-[[3-[[3-[[5-(2-amino-6-oxo-1H-purin-9-yl)-3-[[5-(2-amino-6-oxo-1H-purin-9-yl)-3-hydroxyoxolan-2-yl]methoxy-hydroxyphosphoryl]oxyoxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(5-methyl-2,4-dioxopyrimidin-1-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(6-aminopurin-9-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(6-aminopurin-9-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(6-aminopurin-9-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(6-aminopurin-9-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxyoxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(5-methyl-2,4-dioxopyrimidin-1-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(4-amino-2-oxopyrimidin-1-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(5-methyl-2,4-dioxopyrimidin-1-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(5-methyl-2,4-dioxopyrimidin-1-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(6-aminopurin-9-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(6-aminopurin-9-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(4-amino-2-oxopyrimidin-1-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(4-amino-2-oxopyrimidin-1-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(4-amino-2-oxopyrimidin-1-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(6-aminopurin-9-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(4-amino-2-oxopyrimidin-1-yl)oxolan-2-yl]methyl [5-(6-aminopurin-9-yl)-2-(hydroxymethyl)oxolan-3-yl] hydrogen phosphate Polymers Cc1cn(C2CC(OP(O)(=O)OCC3OC(CC3OP(O)(=O)OCC3OC(CC3O)n3cnc4c3nc(N)[nH]c4=O)n3cnc4c3nc(N)[nH]c4=O)C(COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3CO)n3cnc4c(N)ncnc34)n3ccc(N)nc3=O)n3cnc4c(N)ncnc34)n3ccc(N)nc3=O)n3ccc(N)nc3=O)n3ccc(N)nc3=O)n3cnc4c(N)ncnc34)n3cnc4c(N)ncnc34)n3cc(C)c(=O)[nH]c3=O)n3cc(C)c(=O)[nH]c3=O)n3ccc(N)nc3=O)n3cc(C)c(=O)[nH]c3=O)n3cnc4c3nc(N)[nH]c4=O)n3cnc4c(N)ncnc34)n3cnc4c(N)ncnc34)n3cnc4c(N)ncnc34)n3cnc4c(N)ncnc34)O2)c(=O)[nH]c1=O JLCPHMBAVCMARE-UHFFFAOYSA-N 0.000 description 2
- 229960002685 biotin Drugs 0.000 description 2
- 235000020958 biotin Nutrition 0.000 description 2
- 239000011616 biotin Substances 0.000 description 2
- 239000003795 chemical substances by application Substances 0.000 description 2
- 238000010276 construction Methods 0.000 description 2
- 238000004925 denaturation Methods 0.000 description 2
- 230000036425 denaturation Effects 0.000 description 2
- 238000001514 detection method Methods 0.000 description 2
- 238000011161 development Methods 0.000 description 2
- 210000000981 epithelium Anatomy 0.000 description 2
- GNBHRKFJIUUOQI-UHFFFAOYSA-N fluorescein Chemical compound O1C(=O)C2=CC=CC=C2C21C1=CC=C(O)C=C1OC1=CC(O)=CC=C21 GNBHRKFJIUUOQI-UHFFFAOYSA-N 0.000 description 2
- 230000002068 genetic effect Effects 0.000 description 2
- 238000012165 high-throughput sequencing Methods 0.000 description 2
- 101150073223 hisat gene Proteins 0.000 description 2
- 238000003364 immunohistochemistry Methods 0.000 description 2
- 238000001948 isotopic labelling Methods 0.000 description 2
- 210000003734 kidney Anatomy 0.000 description 2
- 238000002595 magnetic resonance imaging Methods 0.000 description 2
- 230000004060 metabolic process Effects 0.000 description 2
- 230000001394 metastastic effect Effects 0.000 description 2
- 238000012986 modification Methods 0.000 description 2
- 230000004048 modification Effects 0.000 description 2
- 230000001575 pathological effect Effects 0.000 description 2
- 230000007170 pathology Effects 0.000 description 2
- 239000013610 patient sample Substances 0.000 description 2
- 238000004321 preservation Methods 0.000 description 2
- 238000004393 prognosis Methods 0.000 description 2
- 238000001228 spectrum Methods 0.000 description 2
- 101150092712 72 gene Proteins 0.000 description 1
- 208000003174 Brain Neoplasms Diseases 0.000 description 1
- 208000005623 Carcinogenesis Diseases 0.000 description 1
- 208000000461 Esophageal Neoplasms Diseases 0.000 description 1
- 208000021309 Germ cell tumor Diseases 0.000 description 1
- 208000008051 Hereditary Nonpolyposis Colorectal Neoplasms Diseases 0.000 description 1
- 208000017095 Hereditary nonpolyposis colon cancer Diseases 0.000 description 1
- 201000005027 Lynch syndrome Diseases 0.000 description 1
- 206010027406 Mesothelioma Diseases 0.000 description 1
- 102000048850 Neoplasm Genes Human genes 0.000 description 1
- 108700019961 Neoplasm Genes Proteins 0.000 description 1
- 208000034176 Neoplasms, Germ Cell and Embryonal Diseases 0.000 description 1
- 206010052399 Neuroendocrine tumour Diseases 0.000 description 1
- 206010030155 Oesophageal carcinoma Diseases 0.000 description 1
- 238000002123 RNA extraction Methods 0.000 description 1
- 206010039491 Sarcoma Diseases 0.000 description 1
- 101150040974 Set gene Proteins 0.000 description 1
- 208000005718 Stomach Neoplasms Diseases 0.000 description 1
- 208000009956 adenocarcinoma Diseases 0.000 description 1
- 230000001919 adrenal effect Effects 0.000 description 1
- 230000003321 amplification Effects 0.000 description 1
- 210000003484 anatomy Anatomy 0.000 description 1
- 230000009286 beneficial effect Effects 0.000 description 1
- 230000004071 biological effect Effects 0.000 description 1
- 239000012472 biological sample Substances 0.000 description 1
- 239000000090 biomarker Substances 0.000 description 1
- 201000006491 bone marrow cancer Diseases 0.000 description 1
- 210000000481 breast Anatomy 0.000 description 1
- 230000036952 cancer formation Effects 0.000 description 1
- 231100000504 carcinogenesis Toxicity 0.000 description 1
- 238000003759 clinical diagnosis Methods 0.000 description 1
- 210000002808 connective tissue Anatomy 0.000 description 1
- 238000002790 cross-validation Methods 0.000 description 1
- 230000007547 defect Effects 0.000 description 1
- 238000003748 differential diagnosis Methods 0.000 description 1
- 239000003814 drug Substances 0.000 description 1
- 201000004101 esophageal cancer Diseases 0.000 description 1
- 238000011156 evaluation Methods 0.000 description 1
- 208000024519 eye neoplasm Diseases 0.000 description 1
- 230000004927 fusion Effects 0.000 description 1
- 210000000232 gallbladder Anatomy 0.000 description 1
- 206010017758 gastric cancer Diseases 0.000 description 1
- 230000005861 gene abnormality Effects 0.000 description 1
- 201000010536 head and neck cancer Diseases 0.000 description 1
- 230000036541 health Effects 0.000 description 1
- 201000005787 hematologic cancer Diseases 0.000 description 1
- 208000024200 hematopoietic and lymphoid system neoplasm Diseases 0.000 description 1
- 206010073071 hepatocellular carcinoma Diseases 0.000 description 1
- 231100000844 hepatocellular carcinoma Toxicity 0.000 description 1
- 230000001900 immune effect Effects 0.000 description 1
- 238000002991 immunohistochemical analysis Methods 0.000 description 1
- 230000006872 improvement Effects 0.000 description 1
- 210000000936 intestine Anatomy 0.000 description 1
- 201000001441 melanoma Diseases 0.000 description 1
- 238000002493 microarray Methods 0.000 description 1
- 238000011206 morphological examination Methods 0.000 description 1
- 208000016065 neuroendocrine neoplasm Diseases 0.000 description 1
- 201000011519 neuroendocrine tumor Diseases 0.000 description 1
- 238000003199 nucleic acid amplification method Methods 0.000 description 1
- 201000008106 ocular cancer Diseases 0.000 description 1
- 210000000496 pancreas Anatomy 0.000 description 1
- 230000036285 pathological change Effects 0.000 description 1
- 231100000915 pathological change Toxicity 0.000 description 1
- 238000012335 pathological evaluation Methods 0.000 description 1
- 210000004994 reproductive system Anatomy 0.000 description 1
- 238000011160 research Methods 0.000 description 1
- 238000007619 statistical method Methods 0.000 description 1
- 210000002784 stomach Anatomy 0.000 description 1
- 201000011549 stomach cancer Diseases 0.000 description 1
- 210000001685 thyroid gland Anatomy 0.000 description 1
- 238000012549 training Methods 0.000 description 1
- 210000004881 tumor cell Anatomy 0.000 description 1
Images
Classifications
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
- C12Q1/00—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions
- C12Q1/68—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions involving nucleic acids
- C12Q1/6876—Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes
- C12Q1/6883—Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes for diseases caused by alterations of genetic material
- C12Q1/6886—Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes for diseases caused by alterations of genetic material for cancer
-
- G—PHYSICS
- G16—INFORMATION AND COMMUNICATION TECHNOLOGY [ICT] SPECIALLY ADAPTED FOR SPECIFIC APPLICATION FIELDS
- G16B—BIOINFORMATICS, i.e. INFORMATION AND COMMUNICATION TECHNOLOGY [ICT] SPECIALLY ADAPTED FOR GENETIC OR PROTEIN-RELATED DATA PROCESSING IN COMPUTATIONAL MOLECULAR BIOLOGY
- G16B30/00—ICT specially adapted for sequence analysis involving nucleotides or amino acids
-
- G—PHYSICS
- G16—INFORMATION AND COMMUNICATION TECHNOLOGY [ICT] SPECIALLY ADAPTED FOR SPECIFIC APPLICATION FIELDS
- G16H—HEALTHCARE INFORMATICS, i.e. INFORMATION AND COMMUNICATION TECHNOLOGY [ICT] SPECIALLY ADAPTED FOR THE HANDLING OR PROCESSING OF MEDICAL OR HEALTHCARE DATA
- G16H50/00—ICT specially adapted for medical diagnosis, medical simulation or medical data mining; ICT specially adapted for detecting, monitoring or modelling epidemics or pandemics
- G16H50/20—ICT specially adapted for medical diagnosis, medical simulation or medical data mining; ICT specially adapted for detecting, monitoring or modelling epidemics or pandemics for computer-aided diagnosis, e.g. based on medical expert systems
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
- C12Q2600/00—Oligonucleotides characterized by their use
- C12Q2600/158—Expression markers
Landscapes
- Health & Medical Sciences (AREA)
- Engineering & Computer Science (AREA)
- Life Sciences & Earth Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Medical Informatics (AREA)
- General Health & Medical Sciences (AREA)
- Pathology (AREA)
- Organic Chemistry (AREA)
- Analytical Chemistry (AREA)
- Physics & Mathematics (AREA)
- Zoology (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Biotechnology (AREA)
- Public Health (AREA)
- Biophysics (AREA)
- Genetics & Genomics (AREA)
- Wood Science & Technology (AREA)
- Biomedical Technology (AREA)
- Immunology (AREA)
- Data Mining & Analysis (AREA)
- Primary Health Care (AREA)
- Biochemistry (AREA)
- Oncology (AREA)
- Molecular Biology (AREA)
- Databases & Information Systems (AREA)
- Hospice & Palliative Care (AREA)
- Microbiology (AREA)
- Epidemiology (AREA)
- General Engineering & Computer Science (AREA)
- Bioinformatics & Computational Biology (AREA)
- Evolutionary Biology (AREA)
- Spectroscopy & Molecular Physics (AREA)
- Theoretical Computer Science (AREA)
- Apparatus Associated With Microorganisms And Enzymes (AREA)
- Eye Examination Apparatus (AREA)
- Measuring Or Testing Involving Enzymes Or Micro-Organisms (AREA)
Abstract
Description
Claims (1)
Priority Applications (1)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
CN201910956560.7A CN110607370B (zh) | 2019-10-10 | 2019-10-10 | 一种用于人体肿瘤分子分型的基因组合及其应用 |
Applications Claiming Priority (1)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
CN201910956560.7A CN110607370B (zh) | 2019-10-10 | 2019-10-10 | 一种用于人体肿瘤分子分型的基因组合及其应用 |
Publications (2)
Publication Number | Publication Date |
---|---|
CN110607370A CN110607370A (zh) | 2019-12-24 |
CN110607370B true CN110607370B (zh) | 2021-03-26 |
Family
ID=68894295
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
CN201910956560.7A Active CN110607370B (zh) | 2019-10-10 | 2019-10-10 | 一种用于人体肿瘤分子分型的基因组合及其应用 |
Country Status (1)
Country | Link |
---|---|
CN (1) | CN110607370B (zh) |
Families Citing this family (1)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
CN113528659A (zh) * | 2020-09-18 | 2021-10-22 | 深圳汇芯生物医疗科技有限公司 | 肾癌和膀胱癌的风险评估装置 |
Citations (2)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
EP2356258A2 (en) * | 2008-11-17 | 2011-08-17 | Veracyte, Inc. | Methods and compositions of molecular profiling for disease diagnostics |
CN105754931A (zh) * | 2016-03-25 | 2016-07-13 | 中国检验检疫科学研究院 | 一种促进人角质细胞激活肿瘤坏死因子信号通路的方法 |
-
2019
- 2019-10-10 CN CN201910956560.7A patent/CN110607370B/zh active Active
Patent Citations (2)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
EP2356258A2 (en) * | 2008-11-17 | 2011-08-17 | Veracyte, Inc. | Methods and compositions of molecular profiling for disease diagnostics |
CN105754931A (zh) * | 2016-03-25 | 2016-07-13 | 中国检验检疫科学研究院 | 一种促进人角质细胞激活肿瘤坏死因子信号通路的方法 |
Non-Patent Citations (2)
Title |
---|
90-gene signature assay for tissue origin diagnosis of brain metastases;Yulong Zheng等;《Journal of Translational Medicine》;20191001;第17卷(第1期);第1-9页 * |
多靶标基因并行检测技术为肿瘤个体化治疗提供新模式;蔡贞等;《分子诊断与治疗杂志》;20131130;第5卷(第6期);第361-366页 * |
Also Published As
Publication number | Publication date |
---|---|
CN110607370A (zh) | 2019-12-24 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
US20230250484A1 (en) | Gene expression profiles to predict breast cancer outcomes | |
Hasenleithner et al. | A clinician’s handbook for using ctDNA throughout the patient journey | |
Bai et al. | Imaging genomics in cancer research: limitations and promises | |
Rutman et al. | Radiogenomics: creating a link between molecular diagnostics and diagnostic imaging | |
US20180068058A1 (en) | Methods and compositions for sample identification | |
US20110177971A1 (en) | Method for diagnosing the stage of a thyroid tumor | |
WO2010123043A1 (ja) | 癌の評価方法 | |
CN106574296A (zh) | 用于测定dna的组织或细胞来源的方法和试剂盒 | |
JP2021516962A (ja) | バリアント検出の改善 | |
CN117165688A (zh) | 用于尿路上皮癌的标志物及其应用 | |
KR20170067137A (ko) | 암 진단용 miRNA 바이오마커 발굴 방법 및 그 이용 | |
CN115896281A (zh) | 甲基化生物标记物、试剂盒及用途 | |
CN110607370B (zh) | 一种用于人体肿瘤分子分型的基因组合及其应用 | |
WO2020194057A1 (en) | Biomarkers for disease detection | |
JP2010131006A (ja) | 神経膠腫予後予測方法、およびそれに用いるキット | |
CN111733242B (zh) | lncRNA AK024561作为卵巢癌诊断标志物的应用 | |
Wu et al. | 92-Gene molecular profiling in identification of cancer origin: a retrospective study in Chinese population and performance within different subgroups | |
CN114599801A (zh) | 用于测试肺癌风险的试剂盒和方法 | |
Denninghoff | Molecular pathology in the new age of personalized medicine | |
Vigliar et al. | The evolving role of interventional cytopathology from thyroid FNA to NGS: Lessons learned at Federico II University of Naples | |
US20220380841A1 (en) | Methods and Kits using Internal Standards to Control for Complexity of Next Generation Sequencing(NGS) Libraries | |
US20230079748A1 (en) | Preparation method, product, and application of circulating tumor dna reference samples | |
Gomase et al. | Oncogenomics | |
Saghir et al. | How reliable are gene expression-based and immunohistochemical biomarkers assessed on a core-needle biopsy? A study of paired core-needle biopsies and surgical specimens in early breast cancer. Cancers 2022; 14 (16) | |
JP2024527142A (ja) | リキッドバイオプシーにおける変異検出の方法 |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
PB01 | Publication | ||
PB01 | Publication | ||
SE01 | Entry into force of request for substantive examination | ||
SE01 | Entry into force of request for substantive examination | ||
GR01 | Patent grant | ||
GR01 | Patent grant | ||
TR01 | Transfer of patent right | ||
TR01 | Transfer of patent right |
Effective date of registration: 20220117 Address after: 318000 No. 41, Wangxi Road, Dongpu community, Dongcheng Street, Huangyan District, Taizhou City, Zhejiang Province Patentee after: ZHEJIANG SHENGTING BIOLOGICAL SCIENCE & TECHNOLOGY CO.,LTD. Patentee after: Hangzhou Shengting Medical Technology Co.,Ltd. Address before: 318000 No. 41, Wangxi Road, Dongpu community, Dongcheng Street, Huangyan District, Taizhou City, Zhejiang Province Patentee before: ZHEJIANG SHENGTING BIOLOGICAL SCIENCE & TECHNOLOGY CO.,LTD. Effective date of registration: 20220117 Address after: 318000 No. 41, Wangxi Road, Dongpu community, Dongcheng Street, Huangyan District, Taizhou City, Zhejiang Province Patentee after: ZHEJIANG SHENGTING BIOLOGICAL SCIENCE & TECHNOLOGY CO.,LTD. Address before: 310058 Yuhang Tang Road, Xihu District, Hangzhou, Zhejiang 866 Patentee before: ZHEJIANG University |
|
TR01 | Transfer of patent right | ||
TR01 | Transfer of patent right |
Effective date of registration: 20240828 Address after: 318020 No.41, Wangxi Road, Dongpu community, Dongcheng Street, Huangyan District, Taizhou City, Zhejiang Province Patentee after: Zhejiang Shengting Medical Laboratory Co.,Ltd. Country or region after: China Address before: 318000 No. 41, Wangxi Road, Dongpu community, Dongcheng Street, Huangyan District, Taizhou City, Zhejiang Province Patentee before: ZHEJIANG SHENGTING BIOLOGICAL SCIENCE & TECHNOLOGY CO.,LTD. Country or region before: China Patentee before: Hangzhou Shengting Medical Technology Co.,Ltd. |